2 hours ago
1
Upgrade to High-Speed Internet for only ₱1499/month!
Enjoy up to 100 Mbps fiber broadband, perfect for browsing, streaming, and gaming.
Visit Suniway.ph to learn
FRANKFURT, Germany, Nov. 15, 2025 (GLOBE NEWSWIRE) -- Vnzymes, the new brand and European subsidiary of VTR Biotech Group, today officially announced the grand opening of its office in Frankfurt, marking a significant milestone in the company’s global expansion. The move underscores Vnzymes’ commitment to driving innovation in animal nutrition, industrial enzymes, and sustainable agriculture across Europe and beyond.
Founded on the strong foundation of VTR Biotech’s global resources and scientific expertise, Vnzymes deliver biosolutions that promote sustainability, efficiency, and responsibility. The Frankfurt office will serve as the hub for the company’s European operations, supporting research and development, technical services, and local market development tailored to regional needs.
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
For more than 30 years, VTR Biotech has been dedicated to its mission of ‘Bioscience Impact Tomorrow’, advancing the research, development, and application of enzyme preparations, biosynthetic products, and plant extracts,” said Cindy Chen, CEO of Vnzymes. "With the launch of Vnzymes in Europe, we are creating a platform that not only leverages our global expertise but also addresses local market requirements in animal nutrition and health, delivering real value to our partners, clients, and the communities we serve”.
Starting from Asia, VTR Biotech has established a global sales network across more than 60 countries and regions. Collaborating with research institutions and partners worldwide, the company has played a pivotal role in transforming animal nutrition, health, and sustainable agriculture through biotechnology.
The establishment of Vnzymes in Frankfurt represents a strategic step in VTR Biotech’s international growth. The European office will focus on accelerating innovation in animal nutrition and health, bio-agriculture, and plant extracts, providing sustainable and efficient biosolutions designed to benefit both humanity and the planet.
"As the global market evolves, true globalization is about more than expanding into new territories,” Dr Wang Yufeng, the senior technical director of Vnzymes added. "It’s about delivering meaningful innovations that meet local needs while maintaining a global perspective. Vnzymes is uniquely positioned to achieve this in Europe.”
Vnzymes’ core product portfolio includes xylanase and phytase enzymes, which enhance nutrient digestibility, improve phosphorus utilization, and support intestinal health and growth performance in livestock, as well as natural feed additives derived from Macleaya cordata, which boost feed intake, strengthen immunity, enhance antioxidant capacity, and promote sustainable and healthy animal production.
Media contact
Contact Name: Cindy Chen
Company Name: Vnzymes
Website: www.vnzymes.com
Email:[email protected]
Disclaimer: This content is provided by Vnzymes. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an "as-is" basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/9a669e0e-9a7f-4189-a92a-158ecfd0e66d
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef99d83b-df6b-49f9-870a-58a9403fa172
https://www.globenewswire.com/NewsRoom/AttachmentNg/4b9cd0ca-9e29-4f99-99d3-df934aea9edf
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a420993-debb-4277-87c0-2707fe114079
https://www.globenewswire.com/NewsRoom/AttachmentNg/8012bda3-0b3d-4366-a1c3-65e3663069df
